Antibe Therapeutics

The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body.[4] Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.[5] Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). ATB-346 is being developed to address osteoarthritis, although Antibe intends to broaden its application to other types of chronic pain and diseases now treated with NSAIDs. Unlike standard naproxen, ATB-346 does not induce damage to the gastrointestinal tract.[6]

In May 2014, the company announced that it had completed pre-clinical studies on ATB-346.[7] In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials.[8] In mid-January 2015, the company announced that clinical trials for its ATB-346 were being suspended due to safety concerns; clinical trials were restarted in March 2015.[9]

On March 20, 2018, Antibe Therapeutics announced successful results for Phase 2B gastrointestinal safety study for ATB-346.[10] On June 1, 2020, Antibe announced positive results for ATB-346 (now known by its International Nonproprietary Name, otenaproxesul) in its final Phase 2 trial, a dose ranging, efficacy study.[11] The company's second drug, an opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2021.[12]

On November 12, 2020, Antibe Therapeutics has moved to the TSX.

Antibe's products have not yet been approved by the US Food and Drug Administration.

Antibe's science advisory board:[13]

• Andre G. Buret, Professor, University of Calgary, Canada
• Giuseppe Cirino, PhD, Professor, University of Naples, Italy
• Gilberto de Nucci, MD, PhD, Professor, University of Sao Paulo, Brazil
• Peter B. Ernst, DVM, PhD, Professor, UCSD, San Diego, USA
• Derek Gilroy, PhD, Professor, University College, London, UK
• Richard H. Hunt, MD, Emeritus Professor, McMaster University, Canada
• Louis Ignarro, PhD Professor, UCLA, Los Angeles, USA - 1998 Nobel Prize Laureate in Medicine
• Daniel K. Podolsky, MD, President, University of Texas Southwestern Medical Center, USA
• William Sessa, PhD, Professor, Yale University, USA
• Philip M. Sherman, MD, Professor, University of Toronto, Canada

Antibe's board of directors:[14]

• Chair - Walt Macnee, Vice Chair, MasterCard International[15]
• Roderick Flower, Professor Emeritus, Barts and The London School of Medicine and Dentistry
• Dan Legault, CEO, Antibe Therapeutics
• Robert Hoffman, former CFO, Heron Therapeutics; Director, public biotechnology companies
• Amal Khouri, VP Business Development, Knight Therapeutics[16]
• Jennifer McNealey, VP Investor Relations and Strategy, Calithera Biosciences
• John L. Wallace, Chief Scientific Officer, Antibe Therapeutics
• Yung Wu, CEO, MaRS Discovery District[17]

Official website

• Biotechnology Focus: The Need for a Safer NSAID: Can Antibe Therapeutics Deliver One?
• Third International Conference on Medical & Biological Uses of Hydrogen Sulfide